Adverse events184

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 184

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Dry eye	Eye disorders	Placebo-controlled Phase: Placebo	1	103
other	Dry eye	Eye disorders	Placebo-controlled Phase: Apremilast 30 mg BID	0	104
other	Dry eye	Eye disorders	Apremilast Exposure Period: Apremilast 30 mg BID	0	187
other	Dry eye	Eye disorders	Open-label Extension Phase: Apremilast 30 mg BID	1	2
other	Abdominal pain	Gastrointestinal disorders	Placebo-controlled Phase: Placebo	3	103
other	Abdominal pain	Gastrointestinal disorders	Placebo-controlled Phase: Apremilast 30 mg BID	4	104
other	Abdominal pain	Gastrointestinal disorders	Apremilast Exposure Period: Apremilast 30 mg BID	12	187
other	Abdominal pain	Gastrointestinal disorders	Open-label Extension Phase: Apremilast 30 mg BID	0	2
other	Abdominal pain upper	Gastrointestinal disorders	Placebo-controlled Phase: Placebo	2	103
other	Abdominal pain upper	Gastrointestinal disorders	Placebo-controlled Phase: Apremilast 30 mg BID	9	104
other	Abdominal pain upper	Gastrointestinal disorders	Apremilast Exposure Period: Apremilast 30 mg BID	20	187
other	Abdominal pain upper	Gastrointestinal disorders	Open-label Extension Phase: Apremilast 30 mg BID	0	2
other	Constipation	Gastrointestinal disorders	Placebo-controlled Phase: Placebo	3	103
other	Constipation	Gastrointestinal disorders	Placebo-controlled Phase: Apremilast 30 mg BID	0	104
other	Constipation	Gastrointestinal disorders	Apremilast Exposure Period: Apremilast 30 mg BID	3	187
other	Constipation	Gastrointestinal disorders	Open-label Extension Phase: Apremilast 30 mg BID	1	2
other	Diarrhoea	Gastrointestinal disorders	Placebo-controlled Phase: Placebo	21	103
other	Diarrhoea	Gastrointestinal disorders	Placebo-controlled Phase: Apremilast 30 mg BID	43	104
other	Diarrhoea	Gastrointestinal disorders	Apremilast Exposure Period: Apremilast 30 mg BID	74	187
other	Diarrhoea	Gastrointestinal disorders	Open-label Extension Phase: Apremilast 30 mg BID	1	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02307513/events

API reference For AI assistants

Adverse events184

Sources 3

Read this list from software.